FDA/CDC

FDA: Recall of select EpiPen products

Publish date: April 1, 2017
By
Lucas Franki

 

Meridian Medical Technologies has issued a voluntary recall for 13 lots of EpiPen products, according to a press release from the U.S. Food and Drug Administration.

The voluntary recall includes EpiPen and EpiPen Jr. Auto-Injector distributed between Dec. 17, 2015, and July 1, 2016 by Mylan Specialty. Products included in the recall may contain a defective part which would prevent the device from activating.

“While the number of reported failures is small, EpiPen products that potentially contain a defective part are being recalled because of the potential for life-threatening risk if a severe allergic reaction goes untreated,” the FDA said in the press release.

Consumers who need their EpiPens should keep them until a they obtain a replacement, the FDA recommended.

Find the full press release on the FDA website.

Recommended Reading

Peanut-allergic preschoolers benefit from oral immunotherapy
MDedge Pediatrics
Mylan’s generic EpiPen – a price break or marketing maneuver?
MDedge Pediatrics
When should primary care physicians prescribe antibiotics to children with respiratory infection symptoms?
MDedge Pediatrics
EpiPen cost increases far exceed overall medical inflation
MDedge Pediatrics
New-onset pediatric AD phenotype differs from adult AD
MDedge Pediatrics
Children having an anaphylactic attack at school may not get proper treatment
MDedge Pediatrics
Adverse event reporting in second-dose varicella vaccination shows no surprises
MDedge Pediatrics
Lanadelumab reduced hereditary angioedema attacks by 88%-100%
MDedge Pediatrics
Uptick found in severe allergy shot reactions
MDedge Pediatrics
What happens when a baked egg oral challenge is negative?
MDedge Pediatrics

Related Articles